Tim Bilbrough

Tim Bilbrough

Auto-generated profile, based on publicly available information

Tim Bilbrough

Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2022 in Chemical Society Reviews
Verified
Journal Article
Open access
PDF file
TBTim Bilbrough
Tim Bilbrough
EPEmanuele Piemontese
Emanuele Piemontese
OSOliver Seitz
Oliver Seitz
Phosphorylation is a key regulator of protein and cellular function. In this review, we describe tools that enable access to homogeneously phosphorylated protein and discuss examples that demonstrate how they can be applied in functional studies.

7 January 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
JLJoshua Lange
Joshua Lange
RARegan J. Anderson
Regan J. Anderson
AMAndrew J. Marshall
Andrew J. Marshall
SCSusanna T. S. Chan
Susanna T. S. Chan
TBTimothy S. Bilbrough
Timothy S. Bilbrough
GPGavin Painter
Gavin Painter

3 June 2024 in ACS Chemical Biology
Verified
Journal Article
Closed access
TPTheresa E. Pankhurst
Theresa E. Pankhurst
IMIsabelle Montgomerie
Isabelle Montgomerie
AMAndrew Marshall
Andrew Marshall
SDSarah L. Draper
Sarah L. Draper
TBTim Bilbrough
Tim Bilbrough
BCBenjamin Compton
Benjamin Compton

12 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JMJordan J. Minnell
Jordan J. Minnell
MGMitch Ganley
Mitch Ganley
ALAriane R. Lee
Ariane R. Lee
TPTaylah Phabmixay
Taylah Phabmixay
KFKathryn J. Farrand
Kathryn J. Farrand
IHIan Hermans
Ian Hermans
CD8+ tissue-resident memory T cells provide rapid frontline protection at pathogen invasion sites, making them attractive targets for vaccine-mediated immunity. We previously developed an NKT cell-adjuvanted mRNA lipoplex vaccine capable of inducing liver Trm cells and sterile protection against malaria in mice. Here, we show that type I interferon (IFN-I) signalling through dendritic cells — not T cells — is a key brake on liver Trm induction by this vaccine. Optimising mRNA manufacturing to reduce immunostimulatory contaminants substantially dampened IFN-I production, boosted antigen expression in the lymphoid tissues, and drove significantly greater Trm accumulation. These enhanced responses translated into superior protection against parasite challenge. Our findings identify DC-intrinsic IFN-I signalling as a tractable target, and mRNA manufacturing quality as a critical and underappreciated lever, for maximising Trm-based vaccine efficacy.